Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chorioretinitis Scarring in a Neonate Secondary to Congenital Herpes Simplex Type 2.

Journal of vitreoretinal diseases·2026
Same author

Sirolimus in the Management of Complex Infantile Hemangiomas: A State-of-the-Art Review.

Pediatric dermatology·2025
Same author

Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus.

Journal of pediatrics. Clinical practice·2025
Same author

Functional genotype classification groups distinguish disease severity in recessive dystrophic epidermolysis bullosa.

The British journal of dermatology·2025
Same author

Review of encephalocraniocutaneous lipomatosis.

Seminars in pediatric neurology·2024
Same author

Successful treatment of porokeratosis of Mibelli with pathogenesis-directed treatment of topical cholesterol-lovastatin.

Pediatric dermatology·2024

Related Experiment Video

Updated: May 5, 2026

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

780

Propranolol for infantile hemangiomas.

Moise L Levy1

  • 1Moise L. Levy, MD, is physician in chief in Pediatric/Adolescent Dermatology at Dell Children's Medical Center of Central Texas, Austin, Texas.

Global Advances in Health and Medicine
|November 27, 2013
PubMed
Summary

Propranolol, a nonselective beta-blocker, has emerged as a treatment for hemangiomas, common vascular birthmarks. This medication offers an alternative to corticosteroids, addressing concerns about their use.

Keywords:
HemangiomaPHACEarterialbetablockercardiaccorticosteroidseye anomaliesposterior fossa malformationpropranololsegmentaltimololvascular birthmarks

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
Transcutaneous Microcirculatory Imaging in Preterm Neonates
06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

7.8K

Related Experiment Videos

Last Updated: May 5, 2026

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

780
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K
Transcutaneous Microcirculatory Imaging in Preterm Neonates
06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

7.8K

Area of Science:

  • Vascular Biology
  • Dermatology
  • Pediatric Medicine

Background:

  • Hemangiomas are common vascular birthmarks with predictable growth and involution patterns.
  • While most hemangiomas resolve without treatment, interventions are sometimes necessary.
  • Traditional treatments like corticosteroids have limitations, including growth concerns and infection risks.

Observation:

  • A 2008 letter reported the serendipitous effect of propranolol on 9 hemangioma cases.
  • Propranolol, a nonselective beta-blocker, was observed to impact hemangioma growth.
  • This initial observation has been further investigated by multiple research groups.

Findings:

  • Propranolol has demonstrated efficacy in managing hemangiomas.
  • The nonselective beta-blocker offers a potential therapeutic option for specific cases.
  • Further research has expanded on the initial findings regarding propranolol's effects.

Implications:

  • Propranolol represents a significant advancement in hemangioma treatment.
  • It provides a valuable alternative to historical treatments with known complications.
  • Ongoing research continues to define the role and optimal use of propranolol in managing vascular birthmarks.